Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 20 versus AMPHETAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 20 versus AMPHETAMINE.
ADDERALL 20 vs AMPHETAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Amphetamine is a central nervous system stimulant that promotes release of monoamines (dopamine, norepinephrine, and serotonin) from presynaptic terminals and inhibits their reuptake, leading to increased synaptic concentrations. It also reversibly inhibits monoamine oxidase (MAO) and may directly stimulate postsynaptic receptors.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
5-60 mg/day orally, divided into 2-3 doses; immediate-release: initial 5 mg once or twice daily, increase by 5 mg increments weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly
None Documented
None Documented
Clinical Note
moderateAmphetamine + Torasemide
"Amphetamine may increase the hypotensive activities of Torasemide."
Clinical Note
moderateAmphetamine + Tranilast
"Amphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateHydroxyamphetamine + Tranilast
"Hydroxyamphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateDextroamphetamine + Tranilast
"Dextroamphetamine may decrease the sedative activities of Tranilast."
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Terminal elimination half-life: 10-13 hours (adults) for immediate-release formulations; prolonged to 12-14 hours in chronic use. Clinical context: Half-life correlates with duration of action; twice-daily dosing may be needed.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Primarily renal (70-80% as unchanged drug and metabolites); minor biliary/fecal (approximately 2-5%). Urinary pH-dependent: acidic pH enhances elimination, alkaline pH reduces it.
Category C
Category D/X
CNS Stimulant
CNS Stimulant